



## BioVersys AG to Present at the H.C. Wainwright BioConnect Virtual Conference

Basel, Switzerland. January 07, 2021, 2pm CEST

BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today that Marc Gitzinger, Chief Executive Officer at BioVersys, will present a company overview and update on the investment opportunity at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand beginning on Monday January 10 at 7:00am Eastern Standard Time (EST). Management of BioVersys will also host investor meetings January 10-13, 2022.

Conference: H.C. Wainwright Global BioConnect Virtual Conference

Format: On-demand recorded corporate presentation

Date: January 10, 2022 from 7:00 am Eastern Standard Time

Webcast: [BioVersys webcast](#)

### About BioVersys

BioVersys AG is a privately owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company's award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial infections of *Acinetobacter baumannii* (BV100, Phase 1), and tuberculosis (BVL-GSK098, Phase 1) in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. BioVersys is located in the Technologiepark in the thriving biotech hub of Basel.

### BioVersys contacts

**Alina Lundin**, Executive Assistant to CEO, Tel. +41 61 633 22 50; Mail: [info@bioversys.com](mailto:info@bioversys.com)

Website: [www.bioversys.com](http://www.bioversys.com).

